288 related articles for article (PubMed ID: 28287331)
1. Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.
Río J; Rovira À; Tintoré M; Otero-Romero S; Comabella M; Vidal-Jordana Á; Galán I; Castilló J; Arrambide G; Nos C; Tur C; Pujal B; Auger C; Sastre-Garriga J; Montalban X
Mult Scler; 2018 Mar; 24(3):322-330. PubMed ID: 28287331
[TBL] [Abstract][Full Text] [Related]
2. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.
Bermel RA; You X; Foulds P; Hyde R; Simon JH; Fisher E; Rudick RA
Ann Neurol; 2013 Jan; 73(1):95-103. PubMed ID: 23378325
[TBL] [Abstract][Full Text] [Related]
3. Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients.
Romeo M; Martinelli V; Rodegher M; Perego E; Maida S; Sormani MP; Comi G;
Eur J Neurol; 2015 Jun; 22(6):973-80. PubMed ID: 25846708
[TBL] [Abstract][Full Text] [Related]
4. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
[TBL] [Abstract][Full Text] [Related]
5. Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
Goodin DS; Reder AT; Traboulsee AL; Li DK; Langdon D; Cutter G; Cook S; O'Donnell T; Kremenchutzky M; Oger J; Koelbach R; Pohl C; Wicklein EM;
Mult Scler; 2019 May; 25(6):837-847. PubMed ID: 29761737
[TBL] [Abstract][Full Text] [Related]
6. Assessing response to interferon-β in a multicenter dataset of patients with MS.
Sormani MP; Gasperini C; Romeo M; Rio J; Calabrese M; Cocco E; Enzingher C; Fazekas F; Filippi M; Gallo A; Kappos L; Marrosu MG; Martinelli V; Prosperini L; Rocca MA; Rovira A; Sprenger T; Stromillo ML; Tedeschi G; Tintorè M; Tortorella C; Trojano M; Montalban X; Pozzilli C; Comi G; De Stefano N;
Neurology; 2016 Jul; 87(2):134-40. PubMed ID: 27306626
[TBL] [Abstract][Full Text] [Related]
7. Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
Prosperini L; Mancinelli C; Haggiag S; Cordioli C; De Giglio L; De Rossi N; Galgani S; Rasia S; Ruggieri S; Tortorella C; Pozzilli C; Gasperini C
J Neurol Neurosurg Psychiatry; 2020 Mar; 91(3):271-277. PubMed ID: 31974130
[TBL] [Abstract][Full Text] [Related]
8. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
[TBL] [Abstract][Full Text] [Related]
11. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
12. Long-term prognostic value of longitudinal measurements of blood neurofilament levels.
Häring DA; Kropshofer H; Kappos L; Cohen JA; Shah A; Meinert R; Leppert D; Tomic D; Kuhle J
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32817406
[TBL] [Abstract][Full Text] [Related]
13. New natural history of interferon-beta-treated relapsing multiple sclerosis.
Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
15. Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.
Preziosa P; Pagani E; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35105685
[TBL] [Abstract][Full Text] [Related]
16. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.
Huhn K; Senger D; Utz KS; Schmidt M; Fröhlich K; Waschbisch A; Seifert F; Dörfler A; Lee DH; Linker RA
Mult Scler Relat Disord; 2019 Jan; 27():133-138. PubMed ID: 30384198
[TBL] [Abstract][Full Text] [Related]
17. Long-term evolution of multiple sclerosis disability in the treatment era.
; Cree BA; Gourraud PA; Oksenberg JR; Bevan C; Crabtree-Hartman E; Gelfand JM; Goodin DS; Graves J; Green AJ; Mowry E; Okuda DT; Pelletier D; von Büdingen HC; Zamvil SS; Agrawal A; Caillier S; Ciocca C; Gomez R; Kanner R; Lincoln R; Lizee A; Qualley P; Santaniello A; Suleiman L; Bucci M; Panara V; Papinutto N; Stern WA; Zhu AH; Cutter GR; Baranzini S; Henry RG; Hauser SL
Ann Neurol; 2016 Oct; 80(4):499-510. PubMed ID: 27464262
[TBL] [Abstract][Full Text] [Related]
18. Scoring treatment response in patients with relapsing multiple sclerosis.
Sormani MP; Rio J; Tintorè M; Signori A; Li D; Cornelisse P; Stubinski B; Stromillo Ml; Montalban X; De Stefano N
Mult Scler; 2013 Apr; 19(5):605-12. PubMed ID: 23012253
[TBL] [Abstract][Full Text] [Related]
19. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
Paolillo A; Pozzilli C; Giugni E; Tomassini V; Gasperini C; Fiorelli M; Mainero C; Horsfield M; Galgani S; Bastianello S; Buttinelli C
Eur J Neurol; 2002 Nov; 9(6):645-55. PubMed ID: 12453081
[TBL] [Abstract][Full Text] [Related]
20. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
